AzTrials
AzTrials

Preterm LaborNCT03334877

Prediction of Preterm Labor in Asymptomatic High Risk Women

An observational study of Preterm Labor, run by Zagazig University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study. Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN)at 24 weeks of gestation. Read more about this study

Who is it for?
Ages 18 to 34 years, women only
Conditions the study is for
Preterm Labor
What is being tested?
β -human chorionic gonadotropin
How many people
220 participants
Where
No sites listed yet
Study dates
15 May 2015to 1 Oct 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 34 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study at 24 weeks of gestation.

Who may be able to join

  • There were past history of one or more spontaneous preterm labor or preterm rupture of membranes at less than 37 weeks of gestation.
  • previous spontaneous second trimester miscarriage.
  • previous cervical surgery (large loop excision of the transformation zone, loop electrosurgical excision procedure, laser or cone excision).
  • accidental finding of a cervical length of 25 mm or less in the current pregnancy.

Who cannot join

  • Women who reported prior sexual intercourse (within 24 hours).
  • confirmed or suspected rupture of membranes.
  • vaginal bleeding visible on the swab.

About this study

Official title: Cervicovaginal Fluid B-hCG Versus Fetal Fibronectin Assay in Prediction of Preterm Labor in Asymptomatic High Risk Women

Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study. Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN)at 24 weeks of gestation.

For qualitative assay of both b-hCG and fFN, first vaginal specimens were collected by the following method:

Read more

Specimen collection

A sterile Cusco speculum was introduced into the vagina; the anterior lip of the cervix was grasped with sponge forceps and a cotton-tipped swab was placed into the external part of the endocervical canal (not reaching the internal os) and then into the posterior fornix (each for at least 1 min) to obtain an adequate sample of cervico vaginal secretions. Sampling was performed before doing any cervical manipulation (digital or ultrasound examination) and before introducing any vaginal material (lubricants or medications). The Hologic Specimen Collection Kit is the only acceptable specimen collection system which can be used to collect specimens for this assay. The polyester tipped swab provided in the Specimen Collection Kit should be inserted into the vagina and lightly rotated across the posterior fornix for approximately 10 seconds to absorb the cervico vaginal secretions. Once the specimen is obtained, carefully remove the swab from the vagina and place it into the tube of buffer provided with the Specimen Collection Kit. Two Specimen Collection Device per patient were obtained; one for each assay. Label the Specimen Transport Tubes with the patient's name and any other identifying information required.

All women were then followed up till delivery. Women were categorized into two arms: women who delivered preterm (before 37 completed weeks of gestation) and women who delivered at term (after 37 completed weeks of gestation).

Read the detailed description

Patients and methods

This prospective observational study was undertaken from May 2015to October 2017 at Zagazig university hospitals.This study was approved by the Research Ethical Committee of Zagazig university hospital. Written informed consent was obtained from all participants. Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study. Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin (fFN) at 24 weeks of gestation.

Inclusion criteria:

There were past history of one or more spontaneous preterm labor or preterm rupture of membranes at less than 37 weeks of gestation, previous spontaneous second trimester miscarriage, previous cervical surgery (large loop excision of the transformation zone, loop electro surgical excision procedure, laser or cone excision), or an accidental finding of a cervical length of 25 mm or less in the current pregnancy.

Exclusion criteria:

Women who reported prior sexual intercourse (within 24 hours), or confirmed or suspected rupture of membranes, or who had vaginal bleeding visible on the swab.

Gestational age was confirmed by early obstetric ultrasonography (11-14 weeks of gestation). Participant baseline demographic data, obstetric history, and risk factors were tabulated and analysed.

For qualitative assay of both b-hCG and fFN, first vaginal specimens were collected by the following method:

Specimen collection

A sterile Cusco speculum was introduced into the vagina; the anterior lip of the cervix was grasped with sponge forceps and a cotton-tipped swab was placed into the external part of the endocervical canal (not reaching the internal os) and then into the posterior fornix (each for at least 1 min) to obtain an adequate sample of cervico vaginal secretions. Sampling was performed before doing any cervical manipulation (digital or ultrasound examination) and before introducing any vaginal material (lubricants or medications). The Hologic Specimen Collection Kit is the only acceptable specimen collection system which can be used to collect specimens for this assay. The polyester tipped swab provided in the Specimen Collection Kit should be inserted into the vagina and lightly rotated across the posterior fornix for approximately 10 seconds to absorb the cervico vaginal secretions. Once the specimen is obtained, carefully remove the swab from the vagina and place it into the tube of buffer provided with the Specimen Collection Kit. Two Specimen Collection Device per patient were obtained; one for each assay. Label the Specimen Transport Tubes with the patient's name and any other identifying information required.

Qualitative assessment of β-hCG assessment

The qualitative assay of β-hCGwas performed as a bedside test. The swab was then inserted in a tube containing 0.75 ml of sterile normal saline for dilution. From this sample, three drops were used for a bedside HCG test using ACON-HCG one-step pregnancy test strip (Rapid diagnostic Pvt. Ltd, India). with a detection cut-off value of 25 mIU/ ML.

Qualitative assessment of fFNtest:

It was done using Quick Check fFN test; it is a 10-minute, one-step, visual test. The test strip was removed from the foil pouch and its lower end (indicated by the arrows) was inserted into the tube containing the extraction buffer for 10 minutes. A positive sample contain fFN will result in two lines in test strip and a negative sample will result in one control line in test strip.

All women were then followed up till delivery. Women were categorized into two arms: women who delivered preterm (before 37 completed weeks of gestation) and women who delivered at term (after 37 completed weeks of gestation).

Those women who had iatrogenic preterm labor due to fetal or maternal indications were excluded from the final statistical analysis and were calculated among the women who did not complete follow up. Only women with spontaneous preterm labor were included.

Pregnancy outcome details were obtained from handheld notes, reviewed by trained research midwives, and entered onto the study database. Data entry was checked for inaccuracies contemporaneously by senior research midwives. Women were considered to have the outcome of interest (spontaneous preterm birth) if they had spontaneous onset of labor, or experienced preterm premature rupture of membranes with subsequent premature delivery

Conditions
Preterm Labor
Being tested
β -human chorionic gonadotropin
Medical subject headings
Obstetric Labor, Premature

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • β -human chorionic gonadotropinDiagnostic test

    Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.

Study groups in NCT03334877
Study groupRoleWhat they receive
β -human chorionic gonadotropinCervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
Receives: Diagnostic Test: β -human chorionic gonadotropin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The diagnostic accuracy of qualitative level of cervico vaginal β-hCG versus fetal fibronectin

    Prediction of preterm labor in asymptomatic high risk women during antenatal care.

    Measured: From 24 weeks gestation till delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Nov 2017
  2. Study start15 May 2015
  3. Primary completion10 May 2017
  4. Study completion1 Oct 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
220 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03334877
Sponsor's protocol ID
ZUH 50
Status last verified
Nov 2017
First submitted
3 Nov 2017
Last updated
8 Nov 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Preterm Labor, run by Zagazig University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The diagnostic accuracy of qualitative level of cervico vaginal β-hCG versus fetal fibronectin (time frame: From 24 weeks gestation till delivery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in